The potential adding therapeutic effect of pentoxifylline and/or folic acid for chronic kidney disease patients: randomized controlled trial.

ABSTRACT:

Background/objectives

Chronic kidney disease (CKD) is a highly prevalent, irreversible, and progressive disease associated with a high cardiovascular risk. We aimed to clinically investigate the extra-therapeutic effect of adding therapeutic doses of pentoxifylline (PTX) and/or folic acid (FA) for CKD patients to the standard care on their health-related quality.

Methods

A randomized, prospective, parallel, and controlled clinical trial of CONSORT 80 patients diagnosed with CKD stages 3-5 were stratified by simple randomization into four groups (20 patient/group) and followed up for 6 months.

Control group

received standard usual care therapy only; PTX group: received therapeutic dose of PTX added to standard usual care therapy; FA group: received FA added to standard

SUBMITTER: Galal ARM 

PROVIDER: S-EPMC12363063 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature